Klotho Neurosciences, Inc. (NASDAQ:KLTO) Short Interest Update

Klotho Neurosciences, Inc. (NASDAQ:KLTO) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 2,203,718 shares, a growth of 212.0% from the February 12th total of 706,392 shares. Based on an average trading volume of 6,530,944 shares, the days-to-cover ratio is currently 0.3 days. Currently, 3.3% of the shares of the stock are short sold. Currently, 3.3% of the shares of the stock are short sold. Based on an average trading volume of 6,530,944 shares, the days-to-cover ratio is currently 0.3 days.

Klotho Neurosciences Stock Down 0.0%

Klotho Neurosciences stock traded down $0.00 during mid-day trading on Wednesday, hitting $0.52. 2,219,377 shares of the company’s stock traded hands, compared to its average volume of 3,792,310. The company has a market cap of $38.23 million, a PE ratio of -1.62 and a beta of 9.08. Klotho Neurosciences has a one year low of $0.11 and a one year high of $3.91. The firm has a 50 day moving average price of $0.33 and a 200 day moving average price of $0.45.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Klotho Neurosciences to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Klotho Neurosciences in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Trading of Klotho Neurosciences

Several institutional investors have recently made changes to their positions in KLTO. Jane Street Group LLC acquired a new stake in shares of Klotho Neurosciences in the second quarter valued at about $26,000. XTX Topco Ltd lifted its stake in Klotho Neurosciences by 101.2% in the 4th quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock valued at $46,000 after acquiring an additional 80,768 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Klotho Neurosciences during the 4th quarter worth about $126,000. Geode Capital Management LLC raised its holdings in Klotho Neurosciences by 51.8% in the 4th quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock valued at $142,000 after acquiring an additional 167,905 shares in the last quarter. Finally, Brummer Multi Strategy AB bought a new position in shares of Klotho Neurosciences in the 4th quarter valued at $175,000. 20.07% of the stock is currently owned by institutional investors and hedge funds.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.